Comparison between ganciclovir 0.15% eye gel and acyclovir 3% eye ointment for the treatment of acute herpetic corneal ulcers

1. Dawson CR, Togni B. Herpes simplex eye infections: clinical manifestations, pathogenesis, and management. Surv ophthalomol.1976;25(2):121-35.

2. Pepose J, Keadle T, Morrison L. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy. Am J ophthalmol.2006;141(3):547-77.

3. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea.2001;20(1):1-13.

4. Holland EJ, Brilakis HS, Schwartz GS. Herpes Simplex Keratitis. In: Krachmer JH, Mannis MJ, Holland EJ, editors. Cornea: Elsevier Mosby,2005;1.2.

5. Holland EJ, Schwartz GS. Classification of herpes simplex virus keratitis. Cornea. 1999;18(2):144–54.

6. Dawson CR, Togni B. Herpes simplex eye infections: clinical manifestations, pathogenesis and management. Surv Ophthalmol. 1976;21(2): 121–35.

7. Klein RJ. Pathogenetic mechanisms of recurrent herpes simplex virus infections. Arch Virol. 1976;51(1–2):1–13.

8. Naito T, Shiota H, Mimura Y. Side effects in the treatment of herpetic keratitis. Curr Eye Res. 1987;6(1):237–9.

9. Croxtall JD. Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis(dendritic ulcers). Drugs. 2011;71(5):603–10.

10. Maudgal PC, Van Damme B, Missotten L. Corneal epithelial dysplasia after trifluridine use. Graefes Arch Clin Exp Ophthalmol. 1983;220(1):6–12. 

11. Kaufman HE, Heidelberger C. Therapeutic antiviral action of 5-trifluoromethyl-2′-deoxyuridine in herpes simplex keratitis. Science. 1964; 145(3632):585–6. 

12. Gilbert P, Work K. Trifluorthymidine in the treatment of herpes simplex corneal ulcers. A clinical evaluation. Acta Ophthalmol (Copenh). 1980;58(1): 117–20.

13. Kaufman HE, Varnell ED, Thompson HW. Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis. Arch Ophthalmol. 1998;116(6):777–80.

14. Wilhelmus KR. Therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane database of systematic reviews (Online). 2008;1:CD002898. 27.

15. Wilhelmus KR. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane database of systematic reviews (Online). 2010;12:CD002898.

16. McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 2001;61(8):1153–83. 36.

17. Noble S, Faulds D. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 1998;56(1):115–46.

18. Crumpacker CS. Ganciclovir. N Engl J Med. 1996;335(10):721–9.

19. Trousdale MD, Goldschmidt PL, Nobrega R. Activity of ganciclovir against human adenovirus type-5 infection in cell culture and cotton rat eyes. Cornea. 1994;13(5):435–9.42.

20. De Clercq E, Naesens L, De Bolle L, et al. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol. 2001;11(6):381–95.

21. Zirgan package insert. http://www.bausch.com/en/ECP/Our-Products/Rx- Pharmaceuticals/Rx-Pharmaceuticals-ECP/Zirgan-ECP; v. 2011.

22. Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39(4):597–638. Crumpacker CS. Ganciclovir. N Engl J Med. 1996;335(10):721–9.

23. Castela N, Vermerie N, Chast F, et al. Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: intraocular penetration and efficacy. J Ocul Pharmacol. 1994;10(2):439–51.

24. Clirophta. 1994a. Evaluation de la tolérance locale chez le volontaire sain, après instillations multiples d′un gel ophtalmique de ganciclovir 0,15%, Virgan. Nice, France: Rapport clinique Virgan/F-94-01. Dossier d′AMM.

25. Clirophta. 1994b. Cinétique du ganciclovir dans les larmes, après instillations multiples d’un gel ophtalmique de ganciclovir 0,15%, Virgan, chez le volontaire sain. Nice, France: Rapport clinique Virgan/F-94-02. Dossier d’AMM. 

26. Clirophta. 1994b. Cinétique du ganciclovir dans les larmes, après instillations multiples d’un gel ophtalmique de ganciclovir 0,15%, Virgan, chez le volontaire sain. Nice, France: Rapport clinique Virgan/F-94-02. Dossier d’AMM. 

27. Croxtall JD. Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers). Drugs. 2011;71(5):603–10.

28. Tabbara KF, Al Balushi N. Topical ganciclovir in the treatment of acute herpetic keratitis. Clin Ophthalmol. 2010;4:905–12.

29. Colin J. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin Ophthalmol. 2007;1(4):441–53..29,31,55.

30. Colin J, Hoh HB, Easty DL, et al. Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. Cornea. 1997;16(4):393–9.55.

31.  Colin J. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin Ophthalmol. 2007;1(4):441–53.

32. Transphyto. 1993b. Transphyto. 1993c. Etude Clinique comparative randomisée en simple insu de l′effet de l′instillation de ganciclovir gel ophtalmique dans le traitement de l′herpes cornéen superficiel. Clermont-Ferrand, France: Rapport Clinique No. 47.GV 550/09.90. Dossier d′AMM.

33. Transphyto. 1994. Etude multicentrique comparative de l’effet de l’instillation de Virgan dans l’herpes cornéen superficiel. Clermont-Ferrand, France: Rapport clinique No. 64GV 550/04.92-66GV 550/06.92. Dossier d’AMM. Hoh HB, Hurley C, Claoue C, et al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Br J Ophthalmol. 1996;80(2):140–3.